Advertisement

Clinical Rheumatology

, Volume 30, Issue 1, pp 149–150 | Cite as

Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget’s disease of bone

  • Stergios A. Polyzos
Letter to the Editor

Keywords

Zoledronic Acid Risedronate Dose Interval Pamidronate Postmenopausal Osteoporotic Woman 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosures

None.

References

  1. 1.
    Maricic M (2010) The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol 29:1079–1084CrossRefPubMedGoogle Scholar
  2. 2.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMedGoogle Scholar
  3. 3.
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114:999–1007CrossRefPubMedGoogle Scholar
  4. 4.
    Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR (2010) Prolonged anti-resorptive activity of zoledronate—a randomized controlled trial. J Bone Miner Res 25:2251–2255CrossRefPubMedGoogle Scholar
  5. 5.
    Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR (2009) The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 94:538–544CrossRefPubMedGoogle Scholar
  6. 6.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908CrossRefPubMedGoogle Scholar
  7. 7.
    Merlotti D, Gennari L, Martini G, Valleggi F, De PV, Avanzati A, Nuti R (2007) Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J Bone Miner Res 22:1510–1517CrossRefPubMedGoogle Scholar
  8. 8.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007) Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142–148CrossRefPubMedGoogle Scholar
  9. 9.
    Reid IR, Lyles K, Su G et al (2009) Long-term efficacy of zoledronic acid compared with risedronate in Paget’s disease. J Bone Miner Res 24:S358–S358Google Scholar
  10. 10.
    Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone. J Bone Miner Metab 26:635–641CrossRefPubMedGoogle Scholar
  11. 11.
    Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G, Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget’s disease of bone. Horm Metab Res 41:846–850CrossRefPubMedGoogle Scholar
  12. 12.
    Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109–1117CrossRefPubMedGoogle Scholar
  13. 13.
    Ralston SH, Langston AL, Reid IR (2008) Pathogenesis and management of Paget’s disease of bone. Lancet 372:155–163CrossRefPubMedGoogle Scholar
  14. 14.
    Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2010) Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res 25:20–31CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  1. 1.Second Medical Clinic, Medical SchoolAristotle University of Thessaloniki, Ippokration HospitalThessalonikiGreece

Personalised recommendations